On 23 June 2026, HJ Science Co., Ltd. (HJ Science, 6132.HK) successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEx), raising a total of approximately HKD 1.11 billion. CBI is honored to participate in the due diligence work for this IPO Project.

HJ Science Co., Ltd. is a clinical-stage biotech company founded by a team of industry experts dedicated to researching and developing therapies for autoimmune, metabolic, and oncological diseases. The Company has three Core Products—HJ787, HJ178, and HJ891—all of which are internally developed, small-molecule, NMPA Category 1 innovative drugs.

In this IPO project, CBI primarily assisted the sponsor team in conducting due diligence on the company group, its directors, senior management, shareholders, customers and suppliers, etc. In addition to the basic information such as litigation, bankruptcy, winding-up and media records, CBI also assisted the sponsor team in conducting reference check, reputation intelligence and related company search. The due diligence project globally covered 3 countries and regions, including China, Hong Kong and United States of America.